市场调查报告书

毛细胞白血病的全球市场:各治疗方法、地理的成长率,趋势及预测(2018年~2023年)

Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 660532
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
毛细胞白血病的全球市场:各治疗方法、地理的成长率,趋势及预测(2018年~2023年) Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

毛细胞白血病市场,预计从2018年到2023年的预测期间内,以5%的年复合成长率成长。毛细胞白血病,是异常的淋巴球的积蓄相关的血液癌症的一种。

本报告提供全球毛细胞白血病市场调查,整体市场趋势,产品、各地区的详细趋势,市场成长的影响要素分析,竞争情形,主要企业简介等,总括性汇整。

目录

第1章 简介

  • 市场定义

第2章 调查方法

第3章 摘要整理

第4章 主要影响要素

第5章 市场概要

  • 目前市场方案
  • 波特的五力分析
    • 供应商谈判力
    • 消费者谈判力
    • 新加入厂商的威胁
    • 替代产品与服务的威胁
    • 产业内的竞争

第6章 成长要素,阻碍因素,机会,课题分析(DROC)

  • 市场成长要素
    • 诊断率的上升
    • 老年人口的增加
  • 市场阻碍因素
    • 对于不重要的研究缺乏对症状的认识
    • 地方医院的有限的保健服务
  • 市场机会
  • 主要课题

第7章 市场区隔

  • 各治疗法
    • 化疗
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第8章 竞争情形

  • M&A分析
  • 协定,合作,伙伴关系
  • 新产品的销售

第9章 主要企业

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Biogenomics Limited
  • F. Hoffmann-La Roche AG
  • Incyte Corp.
  • Juno Therapeutics
  • MedImmune
  • Novartis
  • 其他

第10章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 46197

Hairy cell leukemia is a very rare type of cancer, which accounts for approximately 2%, out of all the leukemia's. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow. According to National Organization for Rare Disorders, approximately 600-800 new cases are diagnosed each year in the United States. Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect the hairy cell leukemia. First and foremost diagnostic test is a complete blood profile which clearly indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose, if there is an enlarged spleen, by physical examination. One important confirmation test is presence of hairy cells in the blood in the lab tests. Most of the patients also require bone marrow biopsy for confirmation. Diagnosis rate of hairy cell leukaemia is increased during last two-three decades, which is expected to drives the market in the forecast period.

Key Market Trends

Chemotherapy Segment is Expected to Register a Significant Growth Over the Forecast Period

Based on therapy, it is segmented into chemotherapy and Targeted Therapy. The key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society estimates, there were around 22,840 death from leukemia in 2019. Many companies are focusing on developing breakthrough products for the treatment of hairy cell leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia. Additionally, the increase in funding for companies involved in the research related to hairy cell leukemia is expected to boost the studied market.

North America holds the Largest Share in the Hairy Cell Leukemia Market

The hairy cell leukemia market holds the largest share in North America region due to the presence of high incidence rate, increase in geriatric population and advancements in the treatment of hairy cell leukaemia. According to National Organization for Rare Disorders, Hairy cell leukemia is a rare type of blood cancer, that affects about 6,000 persons in the United States. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool and emerging economies in these regions.

Competitive Landscape

The hairy cell leukemia market is competitive and many of the global players are into the market. For instance - Amgen Inc, AstraZeneca plc, BioGenomics Limited, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Merck KGaA, Merck & Co, Inc. and Pfizer Inc. are providing these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Leukemia Cases
    • 4.2.2 Increase in Diagnosis Rates
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness
    • 4.3.2 Limited Health Services in Rural Hospitals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Targeted Therapy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca plc
    • 6.1.3 BioGenomics Limited
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Incyte Corp
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Merck KGaA
    • 6.1.8 Merck & Co, Inc.
    • 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS